ClinicalTrials.gg
CompletedNCT07757867Updated Aug 11, 2026

Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata

An interventional study of Cetirizine (Zyrtec) and Latanoprost in Microneedling-Assisted Delivery, Cetirizine and Latanoprost, sponsored by Tanta University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 10 months after the study started (first participant enrolled Oct 2022, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Alopecia Areata with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Alopecia Areata · Egypt.

Enrollment
6th of 29
80 · median 50
Started
2022
with 3 others
No phase
14 of 31
4 open now
Registered
31st of 31
by date

Among the 31 studies in Alopecia Areata with a site in Egypt, this one is the 6th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2022, is one of 14 with no phase, and was the 31st registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

7 of the 31 studies in Alopecia Areata with a site in Egypt are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Alopecia Areata with a site in Egypt, or all of them as a file.
02

Study summary

This study planned to measure the effectiveness and safety of microneedling aided administration of cetirizine 1% versus latanoprost 0.01% in alopecia areata.

Read the detailed description

Alopecia areata (AA) is a chronic inflammatory disease affecting the hair follicles with a possible multifactorial origin, most prominently in genetically predisposed patients. It is a common cause of non scarring hair loss that presents in a patchy, confluent, or diffuse pattern. The onset may be at any age and there is no known race or sex preponderance.

The treatment of AA depends on the severity and extent of the disease. Treatment options include topical or intralesional corticosteroids, phototherapy, topical irritants, topical minoxidil, topical tacrolimus, topical vitamin D analogs and platelet rich plasma injection. For resistant cases, psoralen with ultraviolet A light, oral cyclosporine and other immunosuppressants could be beneficial.

Microneedling therapy is becoming popular in management of acne scars and also for facial rejuvenations. Recently it has been shown to stimulate hair growth. The proposed mechanism of action is thought to be stimulation of dermal papilla and stem cells and also increasing the blood supply to the hair follicles.

Scalp microneedling is a minimally invasive procedure in which various micro-channels are created by short fine needles to help in penetration and absorption of various agents into the skin. So, microneedling is a promising and effective therapy for the treatment of AA

03

Conditions studied

  • Microneedling-Assisted Delivery
  • Cetirizine
  • Latanoprost
  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed cases of alopecia areata.
  • Patients of any age.
  • Both male and female patients.
  • Recent-onset patchy alopecia areata of ≤6 months' duration.
  • Presence of no more than two alopecia patches.
  • Stationary course of the disease.
  • Willingness to participate in the study.
  • Provision of written or parental/guardian consent for minors.

Exclusion criteria

Exclusion Criteria:

  • Extensive alopecia areata, including alopecia totalis or alopecia universalis.
  • Previous treatment of the alopecia areata lesions.
  • Active scalp infection.
  • Presence of associated dermatological, systemic, or comorbidities.
  • Known allergy or to any of the planned therapeutic agents.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Group A

    Patients treated with microneedling-aided administration of topical cetirizine 1% solution.

    Drug: Cetirizine (Zyrtec)

  • Experimental
    Group B

    Patients treated with microneedling-aided administration of topical latanoprost 0.01% solution.

    Drug: Latanoprost

  • Active comparator
    group C

    Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group

    Drug: Triamcinolone Acetonide

  • Active comparator
    Group D

    Patients treated with microneedling only as a negative control group

    Procedure: Microneedling only

Interventions

  • Patinets treated with microneedling-aided administration of topical cetirizine 1% solution

  • Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group

  • Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group

  • ProcedureMicroneedling only

    Patientstreated with microneedling only as a negative control group

06

What researchers measure

Primary outcomes

  1. Severity of Alopecia Tool Score (SALT Score)

    The Severity of Alopecia Tool (SALT) score was used to assess the extent of scalp hair loss. The score ranges from 0 to 100, with higher scores indicating greater scalp hair loss. Changes in SALT score from baseline was compared between the treatment groups.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Global assessment of hair regrowth

    Hair regrowth was evaluated by the investigator using standardized clinical photographs and a global assessment scale. The degree of hair regrowth was graded on a 5-point scale ranging from 0 (no regrowth) to 4 (excellent regrowth, ≥75%), with higher scores indicating greater clinical improvement. Assessments were performed at baseline and at the end of the 12-week treatment period.

    Time frame: Baseline and at the end of the 12-week treatment period

  2. Adverse events

    Complications, including pain, erythema, edema, pruritus, infection, post-inflammatory hyperpigmentation, allergic reactions, and any other local or systemic adverse events

    Time frame: Throughout the 12-week study period.

07

Study locations

1 site
  • Tanta University
    Tanta, El-Gharbia Governorate, Egypt 31527, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Oct 2024, 24 months.

Of 21 interventional studies with no phase under Alopecia Areata, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Aug 11, 2026
StartActual
Oct 1, 2022
Primary completionActual
Oct 1, 2024
CompletionActual
Oct 1, 2024
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07757867
Lead sponsor
Tanta University
Responsible party
Yomna Mazid El-Hamd Neinaa (Assistant Professor of Dermatology and Venereology, Tanta University) — Principal investigator
First posted
Aug 11, 2026
Start date
Oct 1, 2022
Primary completion
Oct 1, 2024
Completion
Oct 1, 2024
Last update
Aug 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetirizine · Latanoprost

Start the discussion